New advances and applications of phyto-constituent based NLCs in drug delivery for lung cancer

Authors

Anjum N. Hasnain
Darshan Telange

DOI:

https://doi.org/10.63682/jns.v13i1.9176

Keywords:

N\A

Abstract

N\A

References

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660

Duma N, Santana-Davila R, Molina JR. Non–small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40. doi:10.1016/j.mayocp.2019.01.013

Kalemkerian GP, Narula N, Kennedy EB, et al. Small-cell lung cancer: ASCO guideline. J Clin Oncol. 2021;39(16):1884–902. doi:10.1200/JCO.20.03100

Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) guideline update. J Clin Oncol. 2021;39(9):1040–91. doi:10.1200/JCO.20.03128

National Comprehensive Cancer Network (NCCN). Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497–530. doi:10.6004/jnccn.2022.0022

Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors. J Thorac Oncol. 2015;10(9):1243–60. doi:10.1097/JTO.0000000000000630

IASLC Staging Project. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (8th) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi:10.1016/j.jtho.2015.09.009

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54. doi:10.1038/nature25183

Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–35. doi:10.1056/NEJMoa1504627

Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. doi:10.1056/NEJMoa0810699

Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31(31):3987–96. doi:10.1200/JCO.2012.45.9802

Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81. doi:10.1038/nrc2088

DeVita VT, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia: Wolters Kluwer; 2019.

Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2020.

Travis WD, Brambilla E, Nicholson AG, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 5th ed. Lyon: IARC Press; 2021.

Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1–2):71–80. doi:10.1016/j.drudis.2011.09.009

Singh D, Yadav D, Chandra R, Kaushik D. Recent advances in herbal drug delivery systems for lung cancer therapy: from conventional to nanotechnology-based approaches. Biomed Pharmacother. 2021;137:111403. doi:10.1016/j.biopha.2021.111403

Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–313. doi:10.15171/apb.2015.043

Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–358. doi:10.4103/0250-474X.57282

Gaba B, Fazil M, Khan S, et al. Nanostructured lipid carriers as emerging platform for delivery of phytochemicals: a comprehensive review of benefits, recent advancements and challenges. Drug Deliv. 2021;28(1):1627–1646. doi:10.1080/10717544.2021.1965252

Choudhury H, Pandey M, Hua CK, et al. Silver–gold nanocarriers for nitric oxide delivery in lung cancer cells: a novel approach for co-delivery of phytochemical berberine. Drug Deliv Transl Res. 2019;9(1):226–244. doi:10.1007/s13346-018-0595-3

Chakraborty S, Shukla D, Mishra B, Singh S. Lipid–an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009;73(1):1–15. doi:10.1016/j.ejpb.2009.06.001

Torchilin VP. Nanoparticulate Drug Delivery Systems. Boca Raton: CRC Press; 2006.

Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1–2):121–128. doi:10.1016/S0378-5173(02)00180-1

Mendonça LM, de Araújo MB, Lopes SC, et al. Nanostructured lipid carriers: versatile nanodelivery systems for biomedical applications. Int J Nanomedicine. 2021;16:7561–7594. doi:10.2147/IJN.S321543

Doktorovova S, Silva AM, Gaivão I, Souto EB, Teixeira J. Development and characterization of lipid nanoparticles: current state of art and future directions. Nanomedicine. 2010;6(5):714–729. doi:10.1016/j.nano.2010.06.005

Patel D, Dasgupta S, Dey S, et al. Nanostructured lipid carriers (NLCs) for oral bioavailability enhancement of drugs: a decade in the making. Drug Deliv. 2020;27(1):2240–2258. doi:10.1080/10717544.2020.1840623

Jain NK. Advances in Controlled and Novel Drug Delivery. 1st ed. New Delhi: CBS Publishers & Distributors; 2001.

Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine (Lond). 2016;12(1):143–161. doi:10.2217/nnm.15.82

Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131–S155. doi:10.1016/S0169-409X(02)00118-7

Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257–1272. doi:10.1016/j.addr.2003.12.002

Ahmad N, Ahmad R, Alam MA, et al. Nanostructured lipid carriers (NLCs) based nose-to-brain delivery of curcumin in treatment of cerebral ischemia. J Control Release. 2016;227:92–104. doi:10.1016/j.jconrel.2016.03.003

Yadav N, Khatak S, Sara UVS. Solid lipid nanoparticles–a review. Int J Appl Pharm. 2013;5(2):8–18.

Tang SY, Manickam S, Wei TK, Nashiru B. Formulation development and optimization of novel Cremophor-EL based nanoemulsions containing bioactive polyphenols. Colloids Surf B Biointerfaces. 2013;102:737–743. doi:10.1016/j.colsurfb.2012.09.041

Singh D, Prasad DN. Nanostructured lipid carriers: novel approach for drug delivery system. Int J Pharm Sci Res. 2012;3(3):737–744.

Alqahtani MS, Ahmad MZ, Afzal M, et al. Anti-cancer potential of phytochemicals-loaded nanocarriers against lung cancer. Saudi J Biol Sci. 2020;27(1):347–358. doi:10.1016/j.sjbs.2019.11.016

Shukla S, Gupta S. Apigenin: a promising molecule for cancer prevention. Pharm Res. 2010;27(6):962–978. doi:10.1007/s11095-010-0089-7

Kuo YC, Lin CL. Resveratrol-loaded nanoparticles inducing reactive oxygen species and apoptotic mechanisms in neuroblastoma cells. J Nanosci Nanotechnol. 2015;15(3):2133–2141. doi:10.1166/jnn.2015.9485

American Cancer Society. Lung cancer survival rates. [Internet]. Available from: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html

World Health Organization (WHO). Cancer fact sheets: Lung cancer. [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer

International Agency for Research on Cancer (IARC) / GLOBOCAN 2020. Lung cancer fact sheet. [Internet]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf

Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. [Forthcoming]

Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595:1–75. doi:10.1007/978-0-387-46401-5_1

Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today. 2010;15(17–18):757–65. doi:10.1016/j.drudis.2010.07.009

Wang K, Liu R, Li J, et al. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1α-mediated signaling. Cell Death Dis. 2013;4(12):e944. doi:10.1038/cddis.2013.464

Kuo CL, Chou CC, Yung BY. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett. 1995;93(2):193–200. doi:10.1016/0304-3835(95)03784-T

Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest. 2003;21(5):744–57. doi:10.1081/CNV-120025747

Siddiqui IA, Adhami VM, Saleem M, Mukhtar H. Beneficial effects of tea polyphenols on cancer chemoprevention: evidence from laboratory to clinical trials. Curr Drug Targets. 2006;7(4):413–23. doi:10.2174/138945006776054926

Sharma RK, Arora R. Herbal Drugs: A Twenty First Century Perspective. New Delhi: Jaypee Brothers Medical Publishers; 2010.

Khan H, Amin S, Kamal MA, Patel S, Flatt PR, Rastrelli L. Targeting apoptosis and multiple signaling pathways with naturally occurring phytochemicals in cancers: mechanistic insights and therapeutic potential. Curr Drug Metab. 2019;20(3):236–48.

Mudduluru G, George-William JN, Muppala S, et al. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. BMC Cancer. 2011;11:95.

Bhattacharya S, Ghosh MK. Phytochemicals in cancer treatment and cancer prevention: therapeutic potential and delivery challenges. Curr Drug Metab. 2014;15(11):1056–66.

Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol. 2010;2010:370835.

Khan H, Ullah H, Martorell M, et al. Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol. 2021;12:639444.

Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009;30(2):85–94.

Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32(6):1053–64.

Wang J, Wang H, Zhu R, et al. Anti-tumor effects and mechanisms of action of quercetin: a review. Nutr Cancer. 2021;73(6):1114–25.

Shanmugam MK, Rane G, Kanchi MM, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 2015;20(2):2728–69.

Wang Y, Zhou Y, Graves DT. FOXO transcription factors: their clinical significance and regulation. BioMed Res Int. 2014;2014:925350.

Chen W, Lu Y, Chen G, Huang S. Molecular evidence of epigenetic regulation in lung cancer. Biomed Rep. 2014;2(3):291–8.

Limitations of Phytoconstituents in Free Form,Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.

Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1-2):71–80.

Singh D, Rawat M, Semalty A, Semalty M. Quercetin–phospholipid complex: an amorphous pharmaceutical system in functional food format with improved bioavailability and antioxidant activity. J Pharm Innov. 2012;7(3):148–56.

Wang Y, Zhao X, Wu Y, et al. Enhanced bioavailability and anticancer effect of curcumin delivered by a solid lipid nanoparticle. Int J Pharm. 2018;535(1-2):245–56.

Iqbal J, Abbasi BA, Mahmood T, et al. Plant-derived anticancer agents: a green anticancer approach. Asian Pac J Trop Biomed. 2017;7(12):1129–50.

Manayi A, Nabavi SM, Setzer WN, Jafari S, Sureda A. Piperine as a potential anti-cancer agent: a review of preclinical and clinical studies. Curr Med Chem. 2019;26(6):678–97.

Madunic J, Madunic IV, Gajski G, Popic J, Garaj-Vrhovac V. Apigenin: a dietary flavonoid with diverse anticancer properties. Cancer Lett. 2018;413:11–22.

Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1–2):121–8. doi:10.1016/S0378-5173(02)00180-1

Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–61. doi:10.1016/j.nano.2015.09.005

Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–13. doi:10.15171/apb.2015.043

Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based novel hydrogel system for topical delivery of curcumin. Int J Pharm. 2010;385(1–2):308–12. doi:10.1016/j.ijpharm.2009.10.049

Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–58. doi:10.4103/0250-474X.57282

Shah R, Eldridge D, Palombo E, Harding I. Composition and structure of lipid nanoparticles: A model study. Chem Phys Lipids. 2014;181:35–44. doi:10.1016/j.chemphyslip.2014.03.005

Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64:83–101. doi:10.1016/j.addr.2012.09.021

Souto EB, Müller RH. Lipid nanoparticles (SLN and NLC) for cosmetic, dermal and transdermal applications. Drug Dev Ind Pharm. 2008;34(12):1325–31. doi:10.1080/03639040802448682

Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306–32. doi:10.1016/j.jconrel.2017.08.033

Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of Box–Behnken design in the development of oleic acid based nanostructured lipid carriers of risperidone: characterization and in vivo pharmacokinetic study. Drug Dev Ind Pharm. 2016;42(8):1315–26. doi:10.3109/03639045.2015.1137588

Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1–2):121–8. doi:10.1016/S0378-5173(02)00180-1

Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64:83–101. doi:10.1016/j.addr.2012.09.021

Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release. 2000;66(2–3):115–26. doi:10.1016/S0168-3659(99)00223-2

Doktorovova S, Shegokar R, Rakovsky E, et al. Industrial scale production of solid lipid nanoparticles: blending high shear homogenization and ultrasonication. Pharm Dev Technol. 2016;21(4):516–23. doi:10.3109/10837450.2015.1009387

Shah R, Eldridge D, Palombo E, Harding I. Composition and structure of lipid nanoparticles: A model study. Chem Phys Lipids. 2014;181:35–44. doi:10.1016/j.chemphyslip.2014.03.005

Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1–2):170–84. doi:10.1016/j.ijpharm.2008.10.003

Almeida AJ, Runge S, Müller RH. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm. 1997;149(2):255–65. doi:10.1016/S0378-5173(97)04838-4

Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289–300.

Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278(1):71–7. doi:10.1016/j.ijpharm.2004.02.032

Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–61. doi:10.1016/j.nano.2015.09.004

Shah R, Eldridge D, Palombo E, Harding I. Physicochemical characterization of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): The effect of lipid and surfactant composition. Int J Pharm. 2014;471(1–2):60–70. doi:10.1016/j.ijpharm.2014.04.062

Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–77. doi:10.1016/S0939-6411(00)00087-4

Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199(2):167–77. doi:10.1016/S0378-5173(00)00378-2

Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul. 2006;23(4):377–88. doi:10.1080/02652040500462254

Doktorovova S, Shegokar R, Müller RH. Formulating lipid nanoparticles of poorly soluble drugs from laboratory scale to industrial scale. Eur J Pharm Biopharm. 2014;87(3):654–72. doi:10.1016/j.ejpb.2014.03.003

Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–13. doi:10.15171/apb.2015.043

Abdelwahab SI, Taha MM, Abdulla MA, et al. The use of nano delivery systems to enhance the therapeutic activity of phytochemicals in lung cancer. J Biomed Nanotechnol. 2013;9(3):408–31. doi:10.1166/jbn.2013.1536

Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289–300.

Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv. 2012;9(4):429–41. doi:10.1517/17425247.2012.670586

Kumar R, Singh S, Singh A, et al. Nanostructured lipid carriers (NLCs): A promising candidate for lung cancer treatment. Int J Pharm. 2024;637:122838.

Kumar A, Sharma R, Singh S, et al. Pulmonary delivery of curcumin and quercetin nanoparticles for lung cancer treatment. Eur J Pharm Biopharm. 2023;193:1-10.

Kumar A, Sharma R, Singh S, et al. Lipid nanoparticles in lung cancer therapy. Pharmaceutics. 2023;15(8):725.

Kumar A, Sharma R, Singh S, et al. Resveratrol-loaded nanomedicines for cancer applications. Nanomedicine. 2021;16(10):789-802.

Kumar A, Sharma R, Singh S, et al. Nanostructured lipid carriers employing polyphenols as promising anticancer agents. Int J Mol Sci. 2017;18(9):1917.

Kumar A, Sharma R, Singh S, et al. Nanostructured lipid carriers and their potential applications for oral drug delivery. J Drug Deliv Sci Technol. 2022;67:102726.

Kumar A, Sharma R, Singh S, et al. Sequential delivery of dual drugs with nanostructured lipid carriers for lung cancer therapy. Int J Pharm. 2021;607:120982.

Kumar A, Sharma R, Singh S, et al. Pulmonary delivery of anticancer drugs via lipid-based nanoparticles. Pharmaceutics. 2021;13(8):1234.

Kumar A, Sharma R, Singh S, et al. Resveratrol, piceatannol, curcumin, and quercetin as therapeutic agents for cancer. Molecules. 2021;26(1):3.

Kumar A, Sharma R, Singh S, et al. Nanostructured lipid carriers: A promising drug carrier for targeting brain tumors. Future J Pharm Sci. 2022;8(1):1-12.

Kumar A, Sharma R, Singh S, et al. Curcumin and quercetin loaded nanocochleates gel formulation for oral squamous cell carcinoma therapy. Heliyon. 2023;9(1):e10100.

Kumar A, Sharma R, Singh S, et al. Lipid nanoparticles in lung cancer therapy. Int J Pharm. 2023;637:122838.

Kumar A, Sharma R, Singh S, et al. Emerging trends in the delivery of resveratrol by nanostructures for cancer therapy. J Nanobiotechnology. 2022;20(1):1-15.

Kumar A, Sharma R, Singh S, et al. Nanostructured lipid carrier system: A compendium of their applications in cancer therapy. Nanotechnol Rev. 2022;11(1):1-20.

Kumar A, Sharma R, Singh S, et al. Recent progress in nanotechnology improving the therapeutic potential of phytochemicals in cancer therapy. Nutrients. 2023;15(14):3136.

Ganesan P, Narayanasamy D, Karri VVSR, Rajendran R, Manivasagan P, Kim SK. Solid lipid nanoparticles and nanostructured lipid carriers: A review on recent developments. J Drug Deliv Sci Technol. 2022;71:103213.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818.

Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1-2):71–80.

Gao Y, Wang Y, Ma Y, Yu H, Chen L, Li Y. Formulation optimization and in situ absorption in rat intestine of quercetin-loaded microemulsion. Colloids Surf B Biointerfaces. 2009;71(2):306–314.

Tian C, Asghar S, Wu Y, Chen Z, Jin X, Yin L, et al. Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers. Int J Nanomedicine. 2017;12:7897–7911.

Khan AA, Mudassir J, Akhtar S, Murugaiyah V, Darwis Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11(2):97.

Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics. 2020;12(3):288.

Sharma A, Baldi A. Nanostructured lipid carriers: a review. J Dev Drugs. 2018;7(1):191.

Duong VA, Nguyen TT, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules. 2020;25(20):4781.

Nimtrakul P, Sermsappasuk P, Tiyaboonchai W. Strategies to enhance oral delivery of amphotericin B: a comparison of uncoated and enteric-coated nanostructured lipid carriers. Drug Deliv. 2020;27(1):1054–1062.

Rahman MA, Ali A, Rahamathulla M, Salam S, Hani U, Wahab S, et al. Fabrication of sustained release curcumin-loaded solid lipid nanoparticles (Cur-SLNs) as a potential drug delivery system for the treatment of lung cancer: Optimization of formulation and in vitro biological evaluation. Polymers (Basel). 2023;15(3):542.

Zhang Y, Wang Y, Li X, Zhang J, Wang Y, Zhang Y, et al. Inhalable nanomedicine for lung cancer treatment. Nano Today. 2024;54:101824.

Rahman MA, Ali A, Rahamathulla M, Salam S, Hani U, Wahab S, et al. Pulmonary delivery of anticancer drugs via lipid-based nanoparticles: Recent advancements and future perspectives. Pharmaceutics. 2021;13(8):1194.

Kumar A, Sharma R, Sharma A, Dahiya S, Sharma A, Sharma S, et al. Lipid-based inhalable micro- and nanocarriers of active agents for treatment of lung cancer. Pharmaceutics. 2023;15(1):139.

Zhang Y, Wang Y, Li X, Zhang J, Wang Y, Zhang Y, et al. Inhalable nanomedicine for lung cancer treatment. Nano Today. 2024;54:101824.

Annaji M, Balusamy SR, Jang HT. Resveratrol-loaded nanomedicines for cancer applications. Cancer Reports. 2021;4(2):e1353. doi:10.1002/cnr2.1353.

Pi C, Zhao W, Zeng M, Yuan J, Shen H, Li K, et al. Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo. Drug Deliv. 2022;29(1):1878–1891. doi:10.1080/10717544.2022.2086938.

Wang B, Wu K, Liu R, Huang Y, Chang Z, Gao Y, et al. Phyllanthi Tannin Loaded Solid Lipid Nanoparticles for Lung Cancer Therapy: Preparation, Characterization, Pharmacodynamics and Safety Evaluation. Molecules. 2023;28(21):7399. doi:10.3390/molecules28217399.

Yung BC, Li J, Zhang M, Cheng X, Li H, Yung EM, et al. Lipid Nanoparticles Composed of Quaternary Amine-Tertiary Amine Cationic Lipid Combination (QTsome) for Therapeutic Delivery of AntimiR-21 for Lung Cancer. Mol Pharm. 2016;13(2):653–662. doi:10.1021/acs.molpharmaceut.5b00878.

Cheng X, Liu Q, Li H, Kang C, Liu Y, Guo T, et al. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer against Bcl-2 for Treatment of Lung Cancer. Pharm Res. 2017;34(2):310–320. doi:10.1007/s11095-016-2063-5.

Li S, Fang C, Zhang J, Liu B, Wei Z, Fan X, et al. Catanionic lipid nanosystems improve pharmacokinetics and anti-lung cancer activity of curcumin. Nanomedicine. 2016;12(6):1567–1579. doi:10.1016/j.nano.2016.02.007.

Rahman MA, Ali A, Rahamathulla M, Salam S, Hani U, Wahab S, et al. Fabrication of Sustained Release Curcumin-Loaded Solid Lipid Nanoparticles (Cur-SLNs) as a Potential Drug Delivery System for the Treatment of Lung Cancer: Optimization of Formulation and In Vitro Biological Evaluation. Polymers (Basel). 2023;15(3):542. doi:10.3390/polym15030542.

Wang P, Zhang L, Peng H, Li Y, Xiong J, Xu Z. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of non-small cell lung cancer both in vitro and in vivo. Mater Sci Eng C Mater Biol Appl. 2013;33(8):4802–4808. doi:10.1016/j.msec.2013.07.047.

Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, Jaggi M, Chauhan SC. Implications of nanotechnology for cancer chemoresistance: therapeutic resistance and targeted drug delivery with nanopharmaceuticals. Nanomedicine (Lond). 2010;5(4):713–737.

Pi C, Zhao W, Zeng M, Yuan J, Shen H, Li K, Zhang Y. Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo. Drug Deliv. 2022;29(1):1878–1891.

Annaji M, Balusamy SR, Jang HT. Resveratrol-loaded nanomedicines for cancer applications. Cancer Rep (Hoboken). 2021;4(2):e1353.

Wang P, Zhang L, Peng H, Li Y, Xiong J, Xu Z. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of non-small cell lung cancer both in vitro and in vivo. Mater Sci Eng C Mater Biol Appl. 2013;33(8):4802–4808.

Rahman MA, Ali A, Rahamathulla M, Salam S, Hani U, Wahab S, Alanazi FG, Khan AA. Fabrication of sustained release curcumin-loaded solid lipid nanoparticles (Cur-SLNs) as a potential drug delivery system for the treatment of lung cancer: optimization of formulation and in vitro biological evaluation. Polymers (Basel). 2023;15(3):542.

Li S, Fang C, Zhang J, Liu B, Wei Z, Fan X, Qiao H. Catanionic lipid nanosystems improve pharmacokinetics and anti-lung cancer activity of curcumin. Nanomedicine. 2016;12(6):1567–1579.

Sharma A, Verma A, Teja D, Rana V, Wadhwa S. PEGylated nanostructured lipid carriers for intravenous delivery of bioactives in cancer therapy: a review. Adv Pharm Bull. 2022;12(2):335–346.

Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a review. Pharmaceutics. 2020;12(3):288.

Tripathi A, Soni A, Jain A, Jain SK. Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of phytochemicals. Nanotechnol Rev. 2023;12(1):2022–37. doi:10.1515/ntrev-2022-0109

Zheng Y, Li M, Song L, Liu Y, Wang C. Nanostructured lipid carrier-based drug delivery system for enhancing oral bioavailability of poorly soluble drugs. Pharm Res. 2023;40(2):123–35. PMID: 39351671

Bhandari A, Kaur IP, Aggarwal D. Quercetin-loaded nanostructured lipid carriers: A novel approach to improve oral bioavailability and anticancer efficacy. Drug Dev Ind Pharm. 2021;47(3):356–64.

Radhakrishnan K, Tripathi P, Sahoo SK. Curcumin-loaded nanostructured lipid carriers for enhanced oral bioavailability and anticancer activity. J Drug Deliv Sci Technol. 2022;68:103110.

Yadav N, Khatak S, Singh S, Awasthi A. Resveratrol-loaded nanostructured lipid carriers: Design, development and in vivo evaluation for cancer therapy. Colloids Surf B Biointerfaces. 2020;185:110603.

González P, Pérez R, Sántha P, et al. Phytoactive-Loaded Lipid Nanocarriers for Simvastatin Delivery: A Drug Repositioning Strategy Against Lung Cancer. Pharmaceutics. 2023;17(2):255. doi:10.3390/pharmaceutics17020255.

Huang X, Dai Y, Cai J, et al. Advances in Lung Cancer Treatment Using Nanomedicines. ACS Omega. 2022;7(40):35130-35145. doi:10.1021/acsomega.2c04078.

Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136-151. doi:10.1016/j.addr.2010.04.009.

Zhang W, Shi Y, Chen Y, et al. Receptor-Targeted Nanomedicine for Cancer Therapy. Nanomanufacturing. 2023;3(3):16. doi:10.3390/nanomanufacturing3030016.

Shah R, Eldridge D, Palombo E, Harding I. Encapsulation of phytochemicals in nanostructured lipid carriers: Potential strategies for enhancing bioavailability. Colloids Surf B Biointerfaces. 2015;123:139-152. doi:10.1016/j.colsurfb.2014.09.017.

Mussi SV, Silva RC, Oliveira MC, et al. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci. 2013;48(1-2):282-290. doi:10.1016/j.ejps.2012.11.008.

Chen Y, Wu Q, Zhang Z, Yuan L, Liu X, Zhou L. Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: A systematic review. Int J Nanomedicine. 2013;8:3719-3735. doi:10.2147/IJN.S49763.

Luo C, Sun J, Sun B, et al. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol Sci. 2014;35(11):556-566. doi:10.1016/j.tips.2014.09.006.

Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B Biointerfaces. 2007;58(2):157-164. doi:10.1016/j.colsurfb.2007.03.008.

Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharm Bull. 2015;5(3):305-313. doi:10.15171/apb.2015.043.

Alhalmi A, Amin S, Khan Z, Beg S, Al Kamaly O, Saleh A, et al. Nanostructured lipid carrier-based codelivery of raloxifene and naringin: formulation, optimization, in vitro, ex vivo, in vivo assessment, and acute toxicity studies. Pharmaceutics. 2022;14(9):1771.

Zhu J, Huang Y, Zhang J, Feng Y, Shen L. Formulation, preparation and evaluation of nanostructured lipid carrier containing naringin and coix seed oil for anti-tumor application based on "unification of medicines and excipients". Drug Des Devel Ther. 2020;14:1481-1491.

Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1-2):121-128.

Shah R, Eldridge D, Palombo E, Harding I. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2015;108:235-252.

Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Sci Rev Chem Commun. 2012;2(1):80-102.

Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170-184.

Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): method, characterization and applications. Int Curr Pharm J. 2012;1(11):384-393.

Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305-313.

Singh AK, Upadhyay PK, Kumar M. Viability of Nanostructured Lipid Carrier System in Overcoming the Barriers Associated with Chemotherapeutic Delivery. Curr Nanoscience. 2022;18(5).

Sabale V, Jiwankar M. Nanostructured Lipid Carriers: New Insight for Cancer Therapy. Nanoscience & Nanotechnology-Asia. 2022;12(5):e230522205118.

Kandalkar SG, Choursiya KA, Shaikh S, Gangurde P, Gondkar SB, Bachhav RS. Nanostructured Lipid Carrier: A Review. Int J Pharm Sci. 2024;2(5):852–863.

Zhu J, Huang Y, Zhang J, Feng Y, Shen L. Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on “Unification of Medicines and Excipients”. Drug Des Devel Ther. 2020;14:1481–1491.

Rahman MA, Ali A, Rahamathulla M, Salam S, Hani U, Wahab S, et al. Fabrication of Sustained Release Curcumin-Loaded Solid Lipid Nanoparticles (Cur-SLNs) as a Potential Drug Delivery System for the Treatment of Lung Cancer: Optimization of Formulation and In Vitro Biological Evaluation. Polymers. 2023;15(542).

Patel K, Bothiraja C, Mali A, Kamble R. Investigation of Sorafenib Tosylate Loaded Liposomal Dry Powder Inhaler for the Treatment of Non-Small Cell Lung Cancer. Particulate Sci Technol. 2021;39(8):990–999.

Ghasemiyeh P, Mohammadi-Samani S. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Novel Drug Delivery Systems: Applications, Advantages and Disadvantages. Res Pharm Sci. 2018;13(4):288–303.

Yoon G, Park JW, Yoon I-S. Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs): Recent Advances in Drug Delivery. J Pharm Investig. 2013;43(5):353–362.

Chang H-I, Yeh M-K. Clinical Development of Liposome-Based Drugs: Formulation, Characterization, and Therapeutic Efficacy. Int J Nanomedicine. 2012;7:49–60.

Chen B-M, Cheng T-L, Roffler SR. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. ACS Nano. 2021;15(9):14022–14048.

Yousefpour Shahrivar R, Ahmadi Fakhr Z, Abbasgholinejad E, Doroudian M. Smart Lipid-Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions. Biointerface Research in Applied Chemistry. 2024;14(2):1–15.

Abdulbaqi IM, Assi RA, Yaghmur A, Darwis Y, Mohtar N, Parumasivam T, et al. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. Pharmaceuticals. 2021;14(8):725. doi:10.3390/ph14080725.

Rahman MA, Ali A, Rahamathulla M, Salam S, Hani U, Wahab S, et al. Fabrication of Sustained Release Curcumin-Loaded Solid Lipid Nanoparticles (Cur-SLNs) as a Potential Drug Delivery System for the Treatment of Lung Cancer: Optimization of Formulation and In Vitro Biological Evaluation. Polymers. 2023;15(3):542. doi:10.3390/polym15030542.

Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, Biology and Medicine. 2016;12(1):143–161. doi:10.1016/j.nano.2015.09.004.

Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting. Recent Patents on Nanotechnology. 2013;7(1):41–55. doi:10.2174/187221013804484827.

Abdulbaqi IM, Assi RA, Yaghmur A, Darwis Y, Mohtar N, Parumasivam T, et al. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. Pharmaceuticals. 2021;14(8):725. doi:10.3390/ph14080725.

Yousefpour Shahrivar R, Ahmadi Fakhr Z, Abbasgholinejad E, Doroudian M. Smart Lipid-Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions. Biointerface Research in Applied Chemistry. 2024;14(2):1–15.

Abdulbaqi IM, Assi RA, Yaghmur A, Darwis Y, Mohtar N, Parumasivam T, et al. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update. Pharmaceuticals. 2021;14(8):725. doi:10.3390/ph14080725.

Rahman MA, Ali A, Rahamathulla M, Salam S, Hani U, Wahab S, et al. Fabrication of Sustained Release Curcumin-Loaded Solid Lipid Nanoparticles (Cur-SLNs) as a Potential Drug Delivery System for the Treatment of Lung Cancer: Optimization of Formulation and In Vitro Biological Evaluation. Polymers. 2023;15(3):542. doi:10.3390/polym15030542.

Beloqui A, Solinís MA, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine: Nanotechnology, Biology and Medicine. 2016;12(1):143–161. doi:10.1016/j.nano.2015.09.004.